ARO-CFB / Arrowhead - LARVOL DELTA

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease (clinicaltrials.gov) - P1/2 | N=66 | Active, not recruiting | Sponsor: Arrowhead Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2027 ➔ Sep 2025 | Trial primary completion date: Nov 2026 ➔ Mar 2025

Enrollment closed • Trial completion date • Trial primary completion date • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease (clinicaltrials.gov) - P1/2 | N=66 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Phase classification: P1 ➔ P1/2

Phase classification • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1 trial • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease